Sylvia Dobo

BioCryst Pharmaceuticals (United States) — United States

Medicine · Health Sciences

11h-index730citations36works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Coagulation, Bradykinin, Polyphosphates, and Angioedema(21), Influenza Virus Research Studies(4), Urticaria and Related Conditions(3), Hepatitis B Virus Studies(2), PI3K/AKT/mTOR signaling in cancer(2)

Publications36 total

First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Complement Factor D Inhibitor BCX9930 in Healthy Participants
The Journal of Clinical Pharmacology·2025Open Access
P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
HemaSphere·2022· 6 citedOpen Access
Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects
Clinical Pharmacology in Drug Development·2022· 14 citedOpen Access
Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
Clinical and Translational Allergy·2021· 50 citedOpen Access
Protocole d’utilisation thérapeutique (PUT) et de recueil d’informations du Berotralstat dans le cadre de l’autorisation temporaire d’utilisation de cohorte (ATUc) de l’Agence Nationale de Sécurité du Médicament (ANSM)
La Revue de Médecine Interne·2021
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial
Allergy·2020· 45 citedOpen Access
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial
Journal of Allergy and Clinical Immunology·2020· 155 citedOpen Access
Oral Prophylaxis with Berotralstat (BCX7353) Reduces Use of Standard of Care (SOC) On-demand Medication in Patients with Hereditary Angioedema (HAE): APeX-2 Study Results
Journal of Allergy and Clinical Immunology·2020· 1 citedOpen Access
Gastrointestinal (GI) Adverse Events (AEs) Observed With Berotralstat (BCX7353) Treatment for Hereditary Angioedema (HAE) are Primarily Mild, Self-limited, and Diminish with Time on Treatment
Journal of Allergy and Clinical Immunology·2020· 5 citedOpen Access
Patterns of Treatment and Retreatment of Acute Attacks of Hereditary Angioedema (HAE) with Standard of Care (SOC) On-Demand Medication: Results from the APeX-2 Study
Journal of Allergy and Clinical Immunology·2020
P154 SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY
Annals of Allergy Asthma & Immunology·2019· 3 cited
P150 ORAL PROPHYLAXIS WITH BCX7353 REDUCES HAE ATTACK RATES AND IS WELL-TOLERATED: APEX-2 STUDY RESULTS
Annals of Allergy Asthma & Immunology·2019· 1 cited
Final results from the ZENITH-1 study: Oral administration of plasma kallikrein inhibitor BCX7353 for the treatment of attacks in patients with hereditary angioedema
University of Southern Denmark Research Portal (University of Southern Denmark)·2019· 1 cited
Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial
Journal of Allergy and Clinical Immunology·2019· 6 cited
PHARMACOKINETICS AND PHARMACODYNAMICS OF BCX7353, AN ORAL PLASMA KALLIKREIN INHIBITOR, IN HEALTHY JAPANESE SUBJECTS
Annals of Allergy Asthma & Immunology·2018
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
New England Journal of Medicine·2018· 111 citedOpen Access
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp>‐2 study
Allergy·2018· 39 citedOpen Access
P507 BCX7353: An effective and safe oral prophylaxis against attacks of hereditary angioedema. apex-1 final results
Annals of Allergy Asthma & Immunology·2017
Abstracts from the 10th C1-inhibitor deficiency workshop
Allergy Asthma and Clinical Immunology·2017· 10 citedOpen Access
Single Dose IV Peramivir is Safe and Effective in the Treatment of Pediatric Influenza
Open Forum Infectious Diseases·2017· 3 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

William Sheridan(27), Melanie Cornpropst(20), Emel Aygören‐Pürsün(15), Marcus Maurer(14), Phil Collis(13), Marco Cicardi(9), Henriette Farkas(8), Sharon C. Murray(8), Hilary Longhurst(8), Bruce L. Zuraw(7), William R. Lumry(7), Heather A. Iocca(7), Enikő Nagy(7), Markus Magerl(7), Aarnoud Huissoon(7), P. Collis(7), Jonathan A. Bernstein(6), D. Clemons(6), Anette Bygum(6), Urs C. Steiner(6)